Axiora Medical
Axiora Medical
Engineered for immediate surgical response and structural integration in premier NSW clinical departments.
The Sydney healthcare infrastructure, anchored by critical trauma centers in Westmead, Randwick, and the Royal Prince Alfred Hospital, demand absolute reliability in osteosynthesis materials. As the Australian population continues to age, the incidence of femoral neck fractures, distal tibia fractures, and complex articular joint trauma has risen by 4.2% annually across New South Wales.
Consequently, procurement managers and clinical directors are prioritizing Cannulated Screws that feature superior torque tolerance, optimized thread pitches, and verified biocompatibility profiles. This shift requires suppliers to look beyond basic production and offer deep metallurgical consistency and comprehensive TGA (Therapeutic Goods Administration) conformity.
Our titanium cannulated compression screws are specifically optimized for minimally invasive procedures. By utilizing a hollow core, they allow surgeons to insert a precise K-wire as a guide, reducing surgical intervention times and accelerating postoperative rehabilitation for patients across Australian clinical registries.
Cannulated screws serve as the cornerstone of contemporary internal fixation. To meet the demanding mechanical dynamics within the human skeletal framework, every component must withstand substantial shear, bending, and rotational loads. Below is a comprehensive breakdown of the design architecture integrated into our manufacturing processes:
The primary advantage of a cannulated design is the ability to place the implant over a pre-drilled guidewire. To prevent deviations that could damage cortical bone, the inner cannula must be perfectly concentric. Axiora uses gun-drilling techniques that limit runout to less than 0.02 mm over the entire length of the screw, ensuring absolute tracking fidelity during insertion.
Our raw material comprises exclusively medical-grade titanium alloy (Ti-6Al-4V ELI) conformant to ASTM F136. To enhance osseointegration and limit galvanic corrosion, our screws undergo specialized electrochemical anodization (Type II and Type III). This surface treatment creates a stable, bio-inert titanium oxide outer layer that helps minimize bacterial adhesion and promotes bone-implant interface stabilization.
Sydney's demographic demands require screws capable of securing stable purchase in both high-density cortical bone and compromised osteoporotic cancellous bone. Our variable-pitch threads generate progressive compression as the screw is advanced. The self-tapping, self-drilling cutting flutes clean bone debris away from the path, reducing thermal necrosis risks during insertion.
| Physical Property / Test Parameter | Standard Specification (ASTM F136) | Axiora Quality Benchmark |
|---|---|---|
| Tensile Strength (UTS) | ≥ 860 MPa | 895 - 920 MPa |
| Yield Strength (0.2% Offset) | ≥ 795 MPa | 825 - 840 MPa |
| Elongation at Break | ≥ 10% | 12.5% - 14% |
| Surface Roughness (Ra) | ≤ 0.4 μm | ≤ 0.2 μm (Highly Polished) |
| Concentricity Tolerance | ≤ 0.05 mm | ≤ 0.02 mm (Gun-Drilled) |
From raw metallurgical receipt to cleanroom aseptic packaging, our manufacturing pipeline is ISO 13485:2016 certified.
Axiora Medical Technology (China) Co., Ltd. is a specialized manufacturer focused on the research, development, production, and global supply of high-grade orthopedic implants and trauma surgical instruments. Our product portfolio spans across advanced trauma fixation structures, spinal stabilization setups, reconstructive joint components, sports medicine systems, and clinical instrumentation.
Operating from an 18,600 m² production base, we operate high-throughput CNC centers and testing labs. Axiora caters to medical device brands, public hospital networks, and distributors across Europe, North America, and Australia, providing tailored OEM/ODM manufacturing processes.
Partner With Us| Company Name | Axiora Medical Technology (China) Co., Ltd. |
| Brand | Axiora |
| Established | 2017 |
| Factory Area | 18,600 m² |
| Annual Export Revenue | USD 26 Million |
| Quality Control Staff | 48 Dedicated Specialists |
| R&D Engineers | 86 Engineers |
High-fidelity instrumentation designed to complement our osteosynthesis implant lines in Sydney healthcare facilities.
As the orthopedics sector moves towards patient-specific implant designs, the role of standardized implant lines is shifting to accommodate rapid on-demand customization. Axiora's R&D division is actively collaborating with international materials institutes to pioneer three distinct fields of development:
We are engineering micro-thin Hydroxyapatite (HA) and bioactive glass coatings applied via plasma spray methods. For patients with compromised bone density, these coatings accelerate bone attachment directly to the titanium substrate, mitigating the risks of implant migration or micromotion under load.
In partnership with sensor innovators, we are developing next-generation handpieces and insertion tools that provide real-time torque feedback. This advancement allows surgical teams to determine optimal seating torque in osteoporotic bone structures, helping prevent thread stripping and mechanical failure.
Recognizing the importance of supply-chain reliability for Sydney-based surgical schedules, we have optimized our lead times through air cargo routes. We offer direct-delivery options for emergency trauma components, enabling fast turnaround times for customized implants.
Engineered to support bone stabilization and soft-tissue procedures in Sydney hospitals and clinical networks.
Key information on purchasing requirements, regulatory status, and clinical compatibility for Sydney and international buyers.
Get in touch with our technical sales division to discuss bulk product specifications, custom OEM designs, or local logistics arrangements for the Sydney region.
Send Inquiry Now
